Q39, a novel synthetic Quinoxaline 1,4-Di-N-oxide compound with anti-cancer activity in hypoxia

European Journal of Pharmacology

Volumn 581, Issue 3, 2008, Pages 262-269

  Weng, Qinjie ^a   Wang, Duoduo ^a   Guo, Peng ^b   Fang, Liang ^a   Hu, Yongzhou ^b   He, Qiaojun ^a   Yang, Bo ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Bcl 2 protein family; HIF 1 ; Hypoxia; MAPK; Mitochondria

Indexed keywords

3 (4 BROMOPHENYL) 2 (ETHYLSULFONYL) 6 METHYLQUINOXALINE 1,4 DIOXIDE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL HYPOXIA; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL HYPOXIA; CELL LINE, TUMOR; GENE EXPRESSION REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INHIBITORY CONCENTRATION 50; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; QUINOXALINES; SIGNAL TRANSDUCTION; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38949124380     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.12.006     Document Type: Article

References (39)

1. Aichberger K.J., Mayerhofer M., Krauth M.T., Vales A., Kondo R., Derdak S., Pickl W.F., Selzer E., Deininger M., Druker B.J., Sillaber C., Esterbauer H., and Valent P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res. 65 (2005) 9436-9444
2. Assefa Z., Vantieghem A., Declercq W., Vandenabeele P., Vandenheede J.R., Merlevede W., de Witte P., and Agostinis P. The activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signaling pathways protects HeLa cells from apoptosis following photodynamic therapy with hypericin. J. Biol. Chem. 274 (1999) 8788-8796
3. Chang L., and Karin M. Mammalian MAP kinase signaling cascades. Nature 410 (2001) 37-40
4. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., and Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J. Pharmacol. Exp. Ther. 300 (2002) 787-793
5. Cobb M.H. MAP kinase pathways. Prog Biophys Mol Biol. 71 (1999) 479-500
6. Desplat V., Faucher J.L., Mahon F.X., Dello Sbarba P., Praloran V., and Ivanovic Z. Hypoxia modifies proliferation and differentiation of CD34 (+) CML cells. Stem Cells 20 (2002) 347-354
7. Doi S., Soda H., Oka M., Tsurutani J., Kitazaki T., Nakamura Y., Fukuda M., Yamada Y., Kamihira S., and Kohno S. The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells. Mol. Cancer Ther. 3 (2004) 1397-1402
8. Ghobrial I.M., Witzig T.E., and Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55 (2005) 178-194
9. Guo W.X., Pye Q.N., Williamson K.S., Stewart C.A., Hensley K.L., Kotake Y., Floyd R.A., and Broyles R.H. Mitochondrial dysfunction in choline deficiency-induced apoptosis in cultured rat hepatocytes. Free Radic. Biol. Med. 39 (2005) 641-650
10. Hayward R.L., Macpherson J.S., Cummings J., Monia B.P., Smyth J.F., and Jodrell D.I. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent, Genetic evidence for specificity of the antisense effect. Mol. Cancer Ther. 3 (2004) 169-178
11. Ivanovic Z., Belloc F., Faucher J.L., Cipolleschi M.G., Praloran V., and Dello Sbarba P. Hypoxia maintains and interleukin-3 reduces the pre-colony-forming cell potential of dividing CD34+ murine bone marrow cells. Exp. Hematol. 30 (2002) 67-73
12. Katiyar S.K., Roy A.M., and Baliga M.S. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome C release, and caspase activation. Mol. Cancer Ther. 4 (2005) 207-216
13. Ke Q., and Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70 (2006) 1469-1480
14. Koukourakis M.I., Giatromanolaki A., Sivridis E., Simopoulos C., Turley H., Talks K., Gatter K.C., and Harris A.L. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002) 1192-1202
15. Lee S.R., and Lo E.H. Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation. Stroke 34 (2003) 2704-2709
16. Le-Niculescu H., Bonfoco E., Kasuya Y., Claret F., Green D.R., and Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Mol. Cell Biol. 19 (1999) 751-763
17. Lewis T.S., Shapiro P.S., and Ahn N.G. Signal transduction through MAP kinase cascades. Adv. Cancer Res. 74 (1998) 49-139
18. Luo J., Sun Y., Lin H., Qian Y., Li Z., Leonard S.S., Huang C., and Shi X. Activation of JNK by vanadate induces a Fas-associated death domain (FADD)-dependent death of cerebellar granule progenitors in vitro. J. Biol. Chem. 278 (2003) 4542-4551
19. Mancini M., Anderson B.O., Caldwell E., Sedghinasab M., Paty P.B., and Hockenbery D.M. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiationand apoptosis in a human colon carcinoma cell line. J. Cell Biol. 138 (1997) 449-469
20. Maurer B.J., Metelitsa L.S., Seeger R.C., Cabot M.C., and Reynolds C.P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. 91 (1999) 1138-1146
21. Milella M., Kornblau S.M., Estrov Z., Carter B.Z., Lapillonne H., Harris D., Konopleva M., Zhao S., Estey E., and Andreeff M. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J. Clin. Invest. 108 (2001) 851-859
22. Minamino T., Yujiri T., Papst P.J., Chan E.D., Johnson G.L., and Terada N. MEKK1 suppresses oxidative-stress induced apoptosis of embryonic stem cell derived cardiac myocytes. Proc. Natl. Acad. Sci. U S A. 96 (1999) 15127-15132
23. Minden A., and Karin M. Regulation and function of the JNK subgroup of MAP kinases. Biochim. Biophys. Acta 1333 (1997) 85-104
24. Miranda M.B., Dyer K.F., Grandis J.R., and Johnson D.E. Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic: a requirement for Bcl-XL and XIAP in the prolonged survival of monocytic cells. Leukemia 17 (2003) 390-400
25. Monge A., Martínez-Crespo F.J., López de Ceráin A., Palop J.A., Narro S., Senador V., Marín A., Sainz Y., González M., and Hamilton E. Hypoxia-selective agents derived from 2-quinoxalinecarbonitrile 1, 4-di-N-oxides. J. Med. Chem. 38 (1995) 4488-4494
26. Monge A., Palop J.A., López de Ceráin A., Senador V., Martínez-Crespo F.J., Sainz Y., Narro S., García E., de Miguel C., and González M. Hypoxia-selective agents derived from Quinoxaline 1,4-di-N-oxides. J. Med. Chem. 38 (1995) 1786-1792
27. Nozaki K., Nishimura M., and Hashimoto N. Mitogen-activated protein kinases and cerebral ischemia. Mol. Neurobiol. 23 (2001) 1-19
28. Ogbourne S.M., Suhrbier A., Jones B., Cozzi S.J., Boyle G.M., Morris M., McAlpine D., Johns J., Scott T.M., Sutherland K.P., Gardner J.M., Le T.T., Lenarczyk A., Aylward J.H., and Parsons P.G. Antitumor activity of 3-ingenyl angelate, plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 64 (2004) 2833-2839
29. Rice P.L., Washington M., Schleman S., Beard K.S., Driggers L.J., and Ahnen D.J. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res. 63 (2003) 616-620
30. Rotem R., Heyfets A., Fingrut O., Blickstein D., Shaklai M., and Flescher E. Jasmonates, novel anticancer agents acting directly and selectively on human cancer cell mitochondria. Cancer Res. 65 (2005) 1984-1993
31. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia inducible factor-α1 is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
32. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
33. Sinicrope F.A., and Penington R.C. Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. Mol. Cancer Ther. 4 (2005) 1475-1483
34. Sohda M., Ishikawa H., Masuda N., Kato H., Miyazaki T., Nakajima M., Fukuchi M., Manda R., Fukai Y., Sakurai H., and Kuwano H. Pretreatment evaluation of combined HIF-1α, p53 and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int. J. Cancer 110 (2004) 838-844
35. Tang L., and Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Mol. Cancer Ther. 4 (2005) 1250-1259
36. Wouters B.G., Delahoussaye Y.M., Evans J.W., Birrell G.W., Dorie M.J., Wang J., MacDermed D., Chiu R.K., and Brown J.M. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine. Cancer Res. 61 (2001) 145-152
37. Wu C.C., Chan M.L., Chen W.Y., Tsai C.Y., Chang F.R., and Wu Y.C. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol. Cancer Ther. 4 (2005) 1277-1285
38. Yamanaka K., Rocchi P., Miyake H., Fazli L., Vessella B., Zangemeister-Wittke U., and Gleave M.E. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol. Cancer Ther. 4 (2005) 1689-1698
39. Zhang Q., Oh C.K., Messadi D.V., Duong H.S., Kelly A.P., Soo C., Wang L., and Le A.D. hypoxia-induced HIF-1alpha accumulation is augmented in a co-culture of keloid fibroblasts and human mast cells: involvement of ERK1/2 and PI-3K/Akt. Exp. Cell Res. 312 (2006) 145-155